A case of advanced hepatocarcinoma responding to combination therapy of S-1 and PEG-IFN
Tanisaka, Y.; Seike, H.; Matsumoto, T.; Tanaka, Y.; Tsubouchi, E.; Miyauchi, S.; Iwakawa, K.; Ichikawa, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 36(10): 1761-1763
2009
ISSN/ISBN: 0385-0684 PMID: 19838044 Document Number: 631753
A57 -year-old man. Though chronic hepatitis C was pointed out before, it had been left untreated for about 5 years. He was hospitalized because many venereal diseases had been pointed out in the liver by abdomen ultrasonography. Results of close examination revealed stage IV B with bone metastases, and pulmonary metastases was diagnosed. After consultation, whole-body chemotherapy combining S-1 and PEG-IFN was attempted as of June 26, 2007. S-1 (80 mg/day) was then administered every day for two weeks with drug withdrawal for one week. PEG-IFNalpha-2a (180 microg)was administered once a week. We set three weeks as one course. The liver tumor was markedly reduced, and the pulmonary metastases were also reduced at the completion of 5 courses. The therapeutic effectiveness of this chemotherapy was confirmed by imaging test. The course was favorable, and whole-body chemotherapy was discontinued on January 29, 2008. At this writing in October of 2008, the course has been uneventful. This treatment method is a promising choice for whole-body chemotherapy for advanced hepatocarcinoma in the future. We have added some review of the literature, and the S-1+PEG-IFN combination chemotherapy is reported.